

Comparing remote and face-to-face delivery of eye movement desensitisation and reprocessing (EMDR) therapy for post-traumatic stress disorder in military veterans

Submission date 17/08/2022	Recruitment status Stopped	<input checked="" type="checkbox"/> Prospectively registered
Registration date 30/09/2022	Overall study status Stopped	<input type="checkbox"/> Protocol
Last Edited 07/12/2023	Condition category Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Eye movement desensitization and reprocessing (EMDR) is a type of therapy used for post-traumatic stress disorder (PTSD). By encouraging patients to focus on a traumatic memory while simultaneously receiving stimuli in a rhythmic left-right pattern, such as eye movements, the therapy has been associated with a reduction in traumatic stress symptoms. The main aim of the proposed research is to determine whether remotely delivered EMDR has the potential to reduce traumatic stress symptoms in British military veterans with combat-related PTSD.

Who can participate?

Adult patients who meet specific criteria for combat-related PTSD

What does the study involve?

This is an exploratory study to assess fidelity, adherence and factors that influence the outcome. All treatment will be delivered through Veterans' NHS Wales. Face-to-face treatment will occur in usual clinics; remote treatment will take place via Attend Anywhere. All recruitment and research interviews will be undertaken remotely.

The main aim of the proposed research is to determine whether remotely delivered EMDR has the potential to reduce traumatic stress symptoms in British military veterans with combat-related PTSD.

The main objective is to answer the following research questions:

1. For British military veterans with combat-related PTSD, does remotely delivered EMDR reduce symptoms of PTSD to a significantly greater degree than a waiting list?
2. For British military veterans with combat-related PTSD, does remotely delivered EMDR reduce symptoms of PTSD to a similar degree as face-to-face delivered EMDR?
3. For British military veterans with combat-related PTSD, what is the impact of remotely delivered EMDR on quality of life, functioning, symptoms of depression, symptoms of anxiety,

insomnia, alcohol and illicit substance use, and perceived social support?

4. Is remotely delivered EMDR acceptable to British military veterans with combat-related PTSD and those delivering the intervention?

5. What is the likely effect size of remotely delivered EMDR?

6. What factors may impact the effect and successful roll-out of remotely delivered EMDR for combat-related PTSD, if it is shown to be effective?

7. Can the results from this study be used in the planning of a phase III definitive trial?

8. Is a phase III study advisable and feasible?

What are the possible benefits and risks of participating?

Benefits and risks not provided at time of registration

Where is the study run from?

Cardiff University (United Kingdom)

When is the study starting and how long is it expected to run for?

July 2021 to August 2024

Who is funding the study?

1. Health and Care Research Wales (United Kingdom)

2. TEC Cymru (United Kingdom)

Who is the main contact?

Prof Jonathan Bisson (United Kingdom)

bissonJI@cardiff.ac.uk

Contact information

Type(s)

Principal investigator

Contact name

Prof Jonathan Bisson

ORCID ID

<https://orcid.org/0000-0001-5170-1243>

Contact details

Hadyn Ellis Building

Maindy Road

Cardiff

United Kingdom

CF24 4HQ

+44 (0)29 2068 8486

bissonJI@cardiff.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

301730

Protocol serial number

SPON1872-21, IRAS 301730, CPMS 54173

Study information

Scientific Title

Feasibility randomised controlled trial of remotely delivered eye-movement desensitisation and reprocessing (EMDR) versus face-to-face EMDR for post-traumatic stress disorder (PTSD) in military veterans

Study objectives

The study proposes that remotely delivered eye-movement desensitisation and reprocessing (EMDR) has the potential to reduce traumatic stress symptoms in British military veterans with combat-related PTSD

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 21/04/2022, Wales Research Ethics Committee 5 (Health and Care Research Wales, Castlebridge 4, 15-19 Cowbridge Road East, Cardiff, CF11 9AB, United Kingdom; +44 (0)1686 252101, +44 (0)2920 230457, +44 (0)7920 565664; Wales.REC5@wales.nhs.uk), ref: 22/WA/0062

Study design

Exploratory single-blind randomized parallel-group-assigned controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Combat-related post-traumatic stress disorder (PTSD)

Interventions

Study design:

The study will be an exploratory single-blind randomised parallel group controlled trial with nested process evaluation to assess fidelity, adherence and factors that influence the outcome.

Setting:

All treatment will be delivered through Veterans' NHS Wales. Face-to-face treatment will occur in usual clinics; remote treatment will take place via Attend Anywhere. All recruitment and research interviews will be undertaken remotely.

Sample size:

A standard power calculation is not appropriate for a Phase II exploratory trial but, based on

previous research, we believe that a sample size of 20 per group will be sufficient to allow us to achieve our objectives.

For the qualitative arm of the study, the sample size will be guided by preliminary analysis and constant comparison (comparing and contrasting themes from other interviews) during each data collection phase, until the research team is satisfied that there is data saturation and no new themes which are important to the research question arise.

However, it is helpful to have a guide to sample size for study planning. Based on previous research, we propose that interviews will be conducted with around 10 participants who receive treatment remotely, purposively sampled, and all therapists.

Groups:

1. Eye-movement desensitisation and reprocessing (EMDR) delivered remotely
2. Eye-movement desensitisation and reprocessing (EMDR) delivered face-to-face
3. Waiting list

Intervention Type

Behavioural

Primary outcome(s)

Diagnosis and severity of PTSD measured using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) at baseline, 20 and 40 weeks after randomisation

Key secondary outcome(s)

1. Presence and severity of PTSD symptoms measured using the PTSD Checklist (PCL) at baseline, 20 and 40 weeks after randomisation
2. Core symptoms of PTSD and complex PTSD measured using the International Trauma Questionnaire (ITQ) at baseline, 20 and 40 weeks after randomisation
3. Impairment in functioning measured using the Work and Social Adjustment Scale (WSAS) at baseline, 20 and 40 weeks after randomisation
4. Severity of depression measured using the Patient Health Questionnaire (PHQ-9) at baseline, 20 and 40 weeks after randomisation
5. Severity of generalised anxiety disorder (GAD) measured using the GAD-7 assessment at baseline, 20 and 40 weeks after randomisation
6. Alcohol harm measured using the Alcohol Use Disorders Test (AUDIT-O) at baseline, 20 and 40 weeks after randomisation
7. Nature, severity, and impact of insomnia measured using the Insomnia Severity Index (ISI) at baseline, 20 and 40 weeks after randomisation
8. Health-related, quality of life measured using the EQ5D-5L at baseline, 20 and 40 weeks after randomisation
9. Digital skills measured using a Digital Ability questionnaire at baseline

Completion date

29/08/2024

Reason abandoned (if study stopped)

Lack of staff/facilities/resources

Eligibility

Key inclusion criteria

1. Aged 18 years old and over
2. Informed consent
3. Meet DSM5 criteria for combat-related PTSD
4. Access to stable internet access in a private location

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Psychosis
2. DSM5 severe major depressive episode
3. Substance dependence
4. Change in psychotropic medication within one month
5. Suicidal intent

Date of first enrolment

10/10/2022

Date of final enrolment

19/08/2024

Locations**Countries of recruitment**

United Kingdom

Wales

Study participating centre

Cardiff & Vale University Health Board

University Hospital of Wales,

Heath Park,

Cardiff

United Kingdom

CF14 4XW

Study participating centre**Swansea Bay University Local Health Board**

One Talbot Gateway, Seaway Drive
Seaway Parade Industrial Estate
Baglan
Port Talbot
United Kingdom
SA12 7BR

Study participating centre**Cwm Taf Morgannwg University Local Health Board**

Dewi Sant Hospital
Albert Road
Pontypridd
United Kingdom
CF37 1LB

Study participating centre**Betsi Cadwaladr University Lhb**

Executive Offices, Ysbyty Gwynedd
Penrhosgarnedd
Bangor
United Kingdom
LL57 2PW

Study participating centre**Aneurin Bevan University Lhb**

Headquarters - St Cadoc's Hospital
Lodge Road
Caerleon
Newport
United Kingdom
NP18 3XQ

Sponsor information**Organisation**

Cardiff University

ROR

<https://ror.org/03kk7td41>

Funder(s)

Funder type

Government

Funder Name

Health and Care Research Wales

Alternative Name(s)

Health & Care Research Wales, Health Care Research Wales, Ymchwil lechyd a Gofal Cymru, HCRW

Funding Body Type

Government organisation

Funding Body Subtype

Research institutes and centers

Location

United Kingdom

Funder Name

Llywodraeth Cymru TEC Cymru

Alternative Name(s)

Welsh Government, The Welsh Government

Funding Body Type

Government organisation

Funding Body Subtype

Local government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from the National Centre for Mental Health (NCMH)

IPD sharing plan summary

Available on request

Study outputs

Output type

[HRA research summary](#)

Details

Date created

Date added

28/06/2023

Peer reviewed?

No

Patient-facing?

No